Loading...
ASCO Lung Cancer 20232025-01-27T17:44:02+01:00

ASCO Lung Cancer 2023 – hybrid, Chicago

Lecture Board: Maximilian Hochmair, MD
Medical Writer: Judith Moser, MD
Publishing Editor: Anna Fenzl, PhD

DOWNLOADS

All downloads from ASCO 2023 – lung cancer

ASCO 2023 English Lung Cancer Download

Full report (english)

EXPERT VIDEOS

All video interviews from ASCO Lung Cancer 2023

John Heymach provides an overview on the expected benefits of HER2-selective tyrosine kinase inhibitors compared to anti-HER2-antibodies while highlighting the Beamion Lung 1 data. Moreover, he talks about RET inhibitor sensitivity and resistance in lung cancer and shares which study, presented at this year’s ASCO congress, is most likely to impact standard of care treatment in NSCLC.

Marjorie G. Zauderer explains the correlations between histopathological features and genetics in the setting of malignant mesothelioma, and the potential benefit of studying therapeutically relevant subgroups of patients separately, critically discusses trails using PD-1 checkpoint inhibition in unresectable mesothelioma and once again encourages everyone to explore the poster sessions at the major conferences to interact with colleagues around the world.

Go to Top